OBI Pharma Inc. to attend The 37th Annual J.P. Morgan Healthcare Conference
2018.Dec.28
Company Chairman Mr. Michael N. Chang not guilty for the prosecution by Taiwan Shilin District Court
2018.Dec.19
OBI Pharma Inc. to attend 2019 investor conference hosted by Yuanta
2018.Dec.03
OBI Pharma Inc. to attend the Citi's 2018 Global Healthcare Conference
2018.Nov.30
Announcement of the resolution of the board of directors of the company to issue common shares through rights offering
2018.Nov.23
OBI Pharma Inc. to attend the 2018 Asia Pacific Healthcare Forum, hosted by Goldman Sachs
2018.Nov.23
Clarification on the news article by Up Media and other media groups
2018.Nov.21
OBI Pharma Granted FDA Orphan Drug Designation for OBI-888 for the Treatment of Pancreatic Cancer
2018.Nov.15
Department of Health (DOH) clearance of Adagloxad Simolenin (OBI-822) for a Phase III clinical study in Hong Kong
2018.Nov.12
Investigational Device Exemption (IDE) for the development of OBI-888 was approved by the US Food and Drug Administration (FDA) for its use in OBI-888 Phase I cohort expansion phase
